Since its formation in 1970, JRI Orthopaedics (JRI) has had many breakthroughs in the medical world. The British manufacturer of orthopaedic implants and surgical instrumentation was responsible for such innovations as the Furlong hydroxyapatite-ceramic coated total hip replacement, which was a world first and has gone on to achieve clinical success all over the globe.
New products are constantly being developed by a dedicated team of talented individuals who care deeply about the quality of what they do and the outcome that they can deliver to improve peoples lives. JRI is wholly owned by the charity Orthopaedic Research UK (ORUK) and a large proportion of JRIs profits are Gift-Aided to this charity to fund independent orthopaedic research so that patients can receive even better surgical treatments and outcomes in the future.
Keith Jackson has been the managing director of JRI Orthopaedics since 2010 and has more than two decades of experience with the company. He is a chartered engineer, a chartered director, and a Fellow of both the IMechE and the IoD. Also, Keith is a non-executive director of Medilink where he helps to give business support for members of academic, business, and clinical organisations that work in the medical device sector, and is a non-executive director of the commercial arm of the Devices for Dignity Healthcare Technology Co-operative.
Many additional lessons learned since this article was written